Latest News - LabCorp
Top Corporates Hub
LabCorp
Will Strength in Biotechnology Unit Continue to Drive DHR's Growth?
08.07.2026 15:50
Danaher's Biotechnology segment posts 7% core revenue growth as bioprocessing demand strengthened, even as weaker product demand created headwinds.
3 Mid-Cap Stocks Walking a Fine Line
26.06.2026 10:48
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
2 S&P 500 Stocks for Long-Term Investors and 1 Facing Challenges
10.06.2026 13:53
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH
08.06.2026 16:00
Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH This model expands access and supports adoption of NASHnext®, enabling testing across a wider patient population Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 8, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threateni
Assessing Labcorp (LH) Valuation As Shares Cool And P/E Trails Healthcare Peers
02.06.2026 10:10
Labcorp Holdings stock snapshot Labcorp Holdings (LH) stock has been moving without a clear single catalyst, which leads many investors to focus on its fundamentals, including recent returns, revenue, earnings and its current valuation profile. See our latest analysis for Labcorp Holdings. At a share price of $256.87, Labcorp Holdings has seen its short term share price momentum cool, with the share price down over the past week and three months, while longer term total shareholder returns...
Assessing Labcorp (LH) Valuation As Shares Cool And P/E Trails Healthcare Peers
02.06.2026 10:10
Labcorp Holdings stock snapshot Labcorp Holdings (LH) stock has been moving without a clear single catalyst, which leads many investors to focus on its fundamentals, including recent returns, revenue, earnings and its current valuation profile. See our latest analysis for Labcorp Holdings. At a share price of $256.87, Labcorp Holdings has seen its short term share price momentum cool, with the share price down over the past week and three months, while longer term total shareholder returns...
LH Expands Genetic Testing in CRC Through New Collab: Stock to Gain?
01.06.2026 13:11
Labcorp joins a national CRC trial as exclusive genetic testing provider, expanding Invitae-based testing and supporting cancer research.
3 Cash-Producing Stocks That Concern Us
29.05.2026 15:12
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
29.05.2026 11:00
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (CRC). The trial will evaluate approaches to increase germline genetic testing among at-risk family members, as well as the impact of multigene panel testing on care for newly diagnosed patients. Leveraging its Invitae testing,
Did Labcorp’s (LH) AI Push with Epic and MyLabcorp Just Recast Its Digital Health Ambitions?
22.05.2026 08:24
Earlier in May 2026, Labcorp announced an expanded collaboration with Epic, making its full test menu available through Aura, Epic's unified platform that simplifies lab ordering, interfaces and test access for hospitals and health systems using Epic nationwide. A few days later, Labcorp launched MyLabcorp™, an AI-powered mobile app that uses OpenAI models to provide personalized lab result explanations and health education, highlighting the company's push to integrate advanced technology...
Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time
20.05.2026 11:00
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of MyLabcorp™, an AI-powered mobile app that brings together lab results, AI-enabled features and clinical guideline-based content in a secure, personalized mobile experience. The app is designed to give users additional context about their health and support more informed conversations with healthcare providers.
TNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin Up
14.05.2026 12:37
Tandem Diabetes beats Q1 revenue and earnings estimates as gross margin expands, but shares decline 23.6% after the results announcement.
Labcorp expands Epic pact to make full test menu available on Aura
14.05.2026 10:00
The Labcorp agreement continues the expansion of Aura, which gives healthcare providers access to tests from companies including Quest Diagnostics.
Hims & Hers Stock Plunges Post Q1 Earnings Miss, Gross Margin Down
12.05.2026 15:45
HIMS reports an adjusted loss and a revenue miss in first-quarter 2026 as gross margin decreases, but it lifts its full-year revenue outlook.
Labcorp Holdings (LH) is Positioned to Benefit from Demographic Trends
12.05.2026 12:52
Jensen Investment Management, an asset management company based in the US, released its first-quarter 2025 investor letter for the “Jensen Quality Mid Cap Fund”. A copy of the letter is available to download here. The Jensen Quality Mid Cap Fund aims for long-term growth. The Fund returned -2.53% in Q1 2026, lagging the 0.60% return for […]
Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems
12.05.2026 11:00
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Epic, the nation's leading electronic health record (EHR) supporting hospitals and health systems. Through the collaboration, Labcorp's full test menu will be available through Aura, Epic's unified platform for ordering and receiving lab results. The integration will drive meaningful operational efficiencies, streamline lab ordering for clinicians and care teams
Drug Screening Market Research and Global Forecast Report 2026-2036: Increasing Demand in Various Sectors Such As Workplaces, Criminal Justice Systems, and Drug Treatment Centers
08.05.2026 13:14
The global drug screening market is set to surge from USD 8.29 billion in 2026 to approximately USD 25.3 billion by 2036, growing at a CAGR of 11.8%, according to a forecast report. Key growth drivers include increased workplace safety concerns and the expansion of substance abuse prevention programs. The report segments the market by product type (analyzers, rapid testing devices, consumables, services), sample type (urine, oral fluid, breath, hair), technology, end user, and application areas.
CVS Health Q1 Earnings & Revenues Top Estimates, Stock Up in Pre-Market
06.05.2026 14:45
CVS beats Q1 estimates as revenues hit $100.43B, margins expand, and 2026 guidance is raised. Shares jump 4.8% in pre-market.
Here's Why Labcorp (LH) Is a Great 'Buy the Bottom' Stock Now
06.05.2026 13:55
Labcorp (LH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
1 of Wall Street’s Favorite Stock with Competitive Advantages and 2 We Turn Down
05.05.2026 05:00
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.